Barclays PLC Lineage Cell Therapeutics, Inc. Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
A detailed history of Barclays PLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 211,300 shares of LCTX stock, worth $118,328. This represents 0.0% of its overall portfolio holdings.
Number of Shares
211,300
Previous 211,300
-0.0%
Holding current value
$118,328
Previous $192,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding LCTX
# of Institutions
120Shares Held
94.2MCall Options Held
63.8KPut Options Held
1K-
Broadwood Capital Inc New York, NY41.7MShares$23.3 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$5.35 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.6MShares$4.82 Million0.0% of portfolio
-
Defender Capital, Llc.5MShares$2.8 Million1.58% of portfolio
-
Logos Global Management LP San Francisco, CA5MShares$2.8 Million0.6% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $95.1M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...